Temsirolimus, 98%, an inhibitor of mTOR with an IC50 of 1.76 μM

Name: Temsirolimus, 98%, an inhibitor of mTOR with an IC50 of 1.76 μM | 162635-04-3
Brand: J&K Chemical
SKU: JK628156_10_MG
Price: 105.0 USD
Availability: InStock

Cat. No JK628156_10_MG

Vendor: J&K Chemical

Product Information

Product Name

Temsirolimus, 98%, an inhibitor of mTOR with an IC50 of 1.76 μM

Brand Name

J&K

Product Number

628156

CAS

162635-04-3

SDS Document

View/Download

Certificate of Analysis (COA)

COA not found

General Information

PubChem CID

6918289

IUPAC Name

(1R,2R,4S)-4-(2R)-2-(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo30.3.1.04,9hexatriaconta-16,24,26,28-tetraen-12-ylpropyl-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate

InChI Key

CBPNZQVSJQDFBE-FUXHJELOSA-N

SMILES

CC@@H1CCC@H2CC@@H(/C(=C/C=C/C=C/C@H(CC@H(C(=O)C@@H(C@@H(/C(=C/C@H(C(=O)CC@H(OC(=O)C@@H3CCCCN3C(=O)C(=O)C@@1(O2)O)C@H(C)CC@@H4CCC@H(C@@H(C4)OC)OC(=O)C(C)(CO)CO)C)/C)O)OC)C)C)/C)OC

Safety Information

Storage Condition

Freezer -20℃

References Data Source From Pubchem

Post-translational modifications: Principal regulators of bladder cancer

Publication Name: Molecular Biology Reports

Publication Date: 2026-02-27

DOI: 10.1007/s11033-026-11584-6

LncRNA expression signature correlated with cuproptosis: prognostic implications and insights into immune microenvironment in ovarian cancer

Publication Name: Journal of Molecular Histology

Publication Date: 2026-02-25

DOI: 10.1007/s10735-026-10738-x

MGMT promoter methylation modulates the effect of residual tumor on survival after re-resection of recurrent glioblastoma

Publication Name: Acta Neuropathologica Communications

Publication Date: 2026-02-12

DOI: 10.1186/s40478-026-02234-w

A systems-level machine learning approach uncovers therapeutic targets in clear cell renal cell carcinoma

Publication Name: npj Drug Discovery

Publication Date: 2026-02-09

DOI: 10.1038/s44386-025-00036-z

LncRNA CCAT2 role in female-related cancer progression and diagnosis: a comprehensive review

Publication Name: Clinical and Experimental Medicine

Publication Date: 2026-02-08

DOI: 10.1007/s10238-026-02040-7

Temsirolimus, 98%, an inhibitor of mTOR with an IC50 of 1.76 μM

Product Information

General Information

Safety Information

References Data Source From Pubchem

Post-translational modifications: Principal regulators of bladder cancer

LncRNA expression signature correlated with cuproptosis: prognostic implications and insights into immune microenvironment in ovarian cancer

MGMT promoter methylation modulates the effect of residual tumor on survival after re-resection of recurrent glioblastoma

A systems-level machine learning approach uncovers therapeutic targets in clear cell renal cell carcinoma

LncRNA CCAT2 role in female-related cancer progression and diagnosis: a comprehensive review